MMJ BioPharma’s noble pursuit of scientific advancement has been met with a series of inexplicable roadblocks and bureaucratic hurdles erected by the DEA. In 2018, the company dutifully applied for the necessary licenses to cultivate marijuana for research and development purposes, eagerly anticipating the opportunity to commence clinical trials that could yield life-changing treatments. Yet, despite meticulously following the DEA’s convoluted application process, MMJ BioPharma found itself trapped in a seemingly endless cycle of delays, obfuscation, and stonewalling.
Many growers treat CalMag as an emergency correction for a plant that is already showing…
wyOver the past few years, however, there has been a significant decline in opioid-related fatalities.…
This article originally appeared in High Times’ Spring/Summer 2026 print edition. Get yours here. We put out…
The World Cup crowned a champion. The World Series of Poker (WSOP) handed out its…
A recent survey of nearly 1,000 employers, reported by the Wall Street Journal and covered…
Sharon Stone says she quit cannabis after years of using it to cope with seizures…